Efficacy and safety of dose-dense chemotherapy in urothelial carcinoma. - sprookjes - yvandenbroek - TriplyDB

Efficacy and safety of dose-dense chemotherapy in urothelial carcinoma.

Efficacy and safety of dose-dense chemotherapy in urothelial carcinoma.

http://www.wikidata.org/entity/Q33441139

about

Efficacy and safety of dose-dense chemotherapy in urothelial carcinoma.

http://www.wikidata.org/entity/Q33441139

description

2017 nî lūn-bûn

@nan

2017 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մարտին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Efficacy and safety of dose-dense chemotherapy in urothelial carcinoma.

@ast

Efficacy and safety of dose-dense chemotherapy in urothelial carcinoma.

@en

type

label

Efficacy and safety of dose-dense chemotherapy in urothelial carcinoma.

@ast

Efficacy and safety of dose-dense chemotherapy in urothelial carcinoma.

@en

prefLabel

Efficacy and safety of dose-dense chemotherapy in urothelial carcinoma.

@ast

Efficacy and safety of dose-dense chemotherapy in urothelial carcinoma.

@en

P1433

Q33441139-EBB65A63-71D4-4EFC-8CE3-8514C3F9BE98

P1476

Q33441139-88D4A2E2-3550-40FE-9A40-AEDD26559EA8

P2093

Q33441139-1F7E659E-BF04-4B12-B7E8-40294AD9A7BD

Q33441139-6CB92E26-72FF-4324-A7BC-45733301F076

Q33441139-74F07E41-DB09-4611-B0B4-34DAB373A0FC

Q33441139-82319F2F-F168-4FB5-A244-FA056061C401

Q33441139-8E27538D-EFF5-4496-802C-52C73B2C7118

Q33441139-B37203AF-85A0-4D7C-A880-7E40A5D695DE

Q33441139-D6166145-9169-4F06-92D0-E934DEC7FBD0

P2860

Q33441139-076DD46A-DFC0-467B-8924-58E36B501A0B

Q33441139-177769D0-5402-4E74-96A5-7B05B902060A

Q33441139-1F7BB25B-91ED-410A-9FF0-DF39B874F39D

Q33441139-20505BE5-3132-4E69-B430-5D531745745A

Q33441139-21B62D3F-B24C-4C9A-837A-E70AB24E3C07

Q33441139-31C87374-6596-4BC9-8130-9F46ED6E7BB2

Q33441139-383285F4-214A-41E3-A67E-226594C0A723

Q33441139-3C464D9E-70F5-4A3B-BEBB-B0B7DE2B8921

Q33441139-400B7A6B-F1E2-48EC-B951-566739D5D749

Q33441139-41B7B1CB-1794-485F-BCF3-6BB7DABC5153

P31

Q33441139-29240F91-3CB9-48D5-A941-1E0B492DCE92

P356

Q33441139-0F99AE41-0BF5-4AD6-9DF0-183D61A7CF7D

P407

Q33441139-26195E51-9312-4703-8A6E-14EC4D042B69

P577

Q33441139-8AC1E17C-0777-45A4-BF4B-C089C8D0BC40

P698

Q33441139-926038EE-8D25-409D-B0E3-467A8ECDBE7F

Q33441139-996030E1-DAD4-4F08-88B5-FC2B35274BC5

P932

Q33441139-04AB11E8-36A4-4FEF-A8C8-9B96E74A1A79

P356

ONCOTARGET.16759

P1433

P1476

Efficacy and safety of dose-dense chemotherapy in urothelial carcinoma.

@en

P2093

Chenjing Zhu

http://www.w3.org/2001/XMLSchema#string

Jiaming Liu

http://www.w3.org/2001/XMLSchema#string

Jing Xu

http://www.w3.org/2001/XMLSchema#string

Jing Zhang

http://www.w3.org/2001/XMLSchema#string

Qingfang Li

http://www.w3.org/2001/XMLSchema#string

Qisi Lian

http://www.w3.org/2001/XMLSchema#string

Xuelei Ma

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?

Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors.

Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data.

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity

Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer.

Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases.

Treatment of metastatic urothelial cancer: opportunities for drug discovery and development.

P31

scholarly article

P356

10.18632/ONCOTARGET.16759

http://www.w3.org/2001/XMLSchema#string

P407

P577

2017-03-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28422743

http://www.w3.org/2001/XMLSchema#string

29050347

http://www.w3.org/2001/XMLSchema#string

P932

5642622

http://www.w3.org/2001/XMLSchema#string